U.S. markets close in 2 hours 15 minutes
  • S&P 500

    4,665.78
    +71.16 (+1.55%)
     
  • Dow 30

    35,211.65
    +312.31 (+0.89%)
     
  • Nasdaq

    15,801.98
    +310.32 (+2.00%)
     
  • Russell 2000

    2,261.15
    +15.22 (+0.68%)
     
  • Crude Oil

    71.10
    +2.95 (+4.33%)
     
  • Gold

    1,782.80
    -2.70 (-0.15%)
     
  • Silver

    22.86
    -0.27 (-1.19%)
     
  • EUR/USD

    1.1274
    -0.0046 (-0.41%)
     
  • 10-Yr Bond

    1.5230
    +0.0410 (+2.77%)
     
  • GBP/USD

    1.3298
    -0.0040 (-0.30%)
     
  • USD/JPY

    113.7120
    +0.4020 (+0.35%)
     
  • BTC-USD

    58,711.27
    +4,856.11 (+9.02%)
     
  • CMC Crypto 200

    1,467.87
    +38.94 (+2.73%)
     
  • FTSE 100

    7,109.95
    +65.92 (+0.94%)
     
  • Nikkei 225

    28,283.92
    -467.70 (-1.63%)
     

Opiant Pharmaceuticals Announces Presentations at Two Upcoming Investor Conferences

  • Oops!
    Something went wrong.
    Please try again later.
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

SANTA MONICA, Calif., Aug. 27, 2019 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (OPNT), a specialty pharmaceutical company developing medicines for addictions and drug overdose, will present at the following upcoming investor conferences:

  • 2019 Wells Fargo Securities Healthcare Conference, September 4-5, Boston

    • Thursday, September 5 at 10:20 am

  • H.C. Wainwright 21st Annual Global Healthcare Conference, September 9-10, New York City

    • Monday, September 9 at 3:50 pm

Live webcasts will be available in the investor section of the company's website: www.opiant.com. The webcasts also will be archived for 60 days following the presentations.

About Opiant Pharmaceuticals, Inc.
Opiant Pharmaceuticals, Inc. is a specialty pharmaceutical company developing medicines for addictions and drug overdose. NIDA, a division of the National Institutes of Health, describes addictive disorders as chronic relapsing brain diseases which burden society at both the individual and community levels. Opiant's first drug overdose product, NARCAN® Nasal Spray, is approved for marketing in the U.S. and Canada by its licensee, Adapt Pharmaceuticals, now owned by Emergent BioSolutions Inc. For more information visit: www.opiant.com.

CONTACTS:
For Investor Relations and Media Inquiries:
Lisa Sher
Senior Director, Investor Relations and Communications
Opiant Pharmaceuticals, Inc.
(970) 987-2654
lsher@opiant.com

Dan Ferry
Managing Director
LifeSci Advisors, LLC
Daniel@lifesciadvisors.com
(617) 535-7746